The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).
 
David R. Fogelman
Stock and Other Ownership Interests - GTx
Consulting or Advisory Role - Incyte
 
Mark D. Kochenderfer
No Relationships to Disclose
 
Gene Brian Saylors
Consulting or Advisory Role - Celgene; Onyx
Speakers' Bureau - Millennium
 
Fadi S. Braiteh
Employment - US Oncology
Stock and Other Ownership Interests - Celgene; Insys Therapeutics
Honoraria - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Consulting or Advisory Role - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Caris MPI; Celgene; Genomic Health; Incyte; Insys Therapeutics; Myriad Pharmaceuticals; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Active Biotech (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BIND Therapeutics (Inst); Biomarin (Inst); bioTheranostics (Inst); BN ImmunoTherapeutics (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Celgene (Inst); Cell Therapeutics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Foundation Medicine (Inst); Genomic Health (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); HERON (Inst); ImClone Systems (Inst); Incyte (Inst); Insys Therapeutics (Inst); Janssen (Inst); Lilly (Inst); MEI Pharma (Inst); Merrimack (Inst); Millennium (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); PSMA Development Company (Inst); Roche/Genentech (Inst); Saladax Biomedical (Inst); Sanofi (Inst); Seagen (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Foundation Medicine; Genomic Health; Gilead Sciences; Heron; Incyte; Insys Therapeutics; Lilly; MolecularHealth; Pfizer; Roche/Genentech; Saladax Biomedical; Sanofi
 
John J. Nemunaitis
Stock and Other Ownership Interests - Gradalis
Patents, Royalties, Other Intellectual Property - Gradalis
 
Allen Lee Cohn
Honoraria - Celgene; onyx; Sanofi
Speakers' Bureau - Celgene; Lilly; Sanofi
 
Peter O'Neill
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Li Zhou
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Julie C. Switzky
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Albert Assad
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Johanna C. Bendell
Employment - Parallon (I)